Reviving Cardiac Science
Executive SummaryBoth physicians and the general public share the perception that a sudden cardiac emergency in a hospital will, almost instantly, draw a response team equipped with a crash cart to revive the patient. Recent studies show, however, that average response times can be as high as ten minutes in situations where each minute that passes diminishes the patient's survival rate by 10%. Cardiac Science's technology continuously monitors patients, detects a rhythm problem and delivers defibrillation shocks to return the patient to normal rhythm in an average response time of 21 seconds. Some physicians, however, remain skeptical about the need for such technology, presenting the company with the challenge of convincing clinicians to alter longstanding practice patterns.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.